MedTrace Logo

Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

NCT00243152 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-12-07

Study results available
· View outcomes & findings →

Summary

The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine (trade name Lamictal) on neuropathic facial pain or neuralgia using functional magnetic resonance imaging (fMRI).

Conditions

  • Facial Neuropathy

Interventions

DRUG

Lamotrigine

: 25mg and 50mg tablets

DRUG

Placebo (for Lamotrigine)

Sugar pill manufactured to mimic Lamotrigine tablets

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Pain and Analgesia Imaging and Neuroscience Group

    lead OTHER

Principal Investigators

  • David Borsook, M.D., Ph.D. · Mclean Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243152 on ClinicalTrials.gov